The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A.sub.2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)